Table 2.
HCV diagnostic and treatment-related information in the included studies.
| Study ID | Study Reported HCV Treatment | Number Treated | Genotypes Detected (Treated) | Drugs by Genotypes and Duration |
|---|---|---|---|---|
| Denis et al. 2000 [37] | Yes | 10 | NR | Interferon |
| Cullen 2005 [27] | Yes | 1 | NR | Interferon |
| Cullen et al. 2006 [28] | Yes | 6 | NR | NR |
| Cullen et al. 2007 [30] | Yes | 3 | NR | NR |
| Jack et al. 2008 [36] | Yes | 30 | Genotype 1 (7), Genotype 3 (14), Genotype unknown (9) | NR |
| Anderson et al. 2009 [33] | Yes | 2 | NR | NR |
| Senn et al. 2009 [25] * | NR | Genotype 1 (43), Genotype 3 (34), Genotype 4 (9) * | ||
| Cullen et al. 2011 [29] | Yes | 4 | NR | NR |
| Seidenberg et al. 2013 [16] | Yes | 35 | Genotype 1 (19), Genotype 3 (13), Genotype 4 (30) | Genotypes 1 and 4—once-weekly injections of peginterferon alfa-2a (180 μg) plus ribavirin (1000 mg or 1200 mg/day) for 48 weeks. Genotype 3—ribavirin 800 mg/day and peginterferon alfa-2a 180 μg/week subcutaneously for 24 weeks. |
| Murtagh et al. 2018 [14] | Yes | 20 | NR | NR |
| Wade et al. 2019 [31] | Yes | 43 | Genotype 1, Genotype 1a, and Genotype 3 | Genotype 1—co-formulated paritaprevir 75 mg, ritonavir 50 mg, and ombitasvir 12.5 mg in two tablets daily plus dasabuvir 250 mg one tablet twice daily for 12 weeks. Genotype 1a—weight-based ribavirin; patients ≤75 kg received 1000 mg and patients ≥75 kg received 1200 mg daily for 12 weeks. Genotype 3—sofosbuvir 400 mg and daclatasvir 60 mg one tablet daily for 12 weeks. |
| Heard et al. 2020 [26] | Yes | 20 | NR | NR |
* The numbers in the parentheses in column four represent only the genotypes detected, NR = Not reported.